These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 33817409)

  • 1. A case of ulcerative colitis associated with teprotumumab treatment for thyroid eye disease.
    Safo MB; Silkiss RZ
    Am J Ophthalmol Case Rep; 2021 Jun; 22():101069. PubMed ID: 33817409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
    Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
    Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Teprotumumab-Related Adverse Events in Thyroid Eye Disease: A Multicenter Study.
    Shah SA; Amarikwa L; Sears CM; Clauss KD; Rajjoub RD; Kang JY; Tamhankar MA; Briceño CA; Harrison AR; Dosiou C; Cockerham KP; Wester ST; Douglas RS; Kossler AL
    Ophthalmology; 2024 Apr; 131(4):458-467. PubMed ID: 37852417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Teprotumumab for the Treatment of Active Thyroid Eye Disease.
    Douglas RS; Kahaly GJ; Patel A; Sile S; Thompson EHZ; Perdok R; Fleming JC; Fowler BT; Marcocci C; Marinò M; Antonelli A; Dailey R; Harris GJ; Eckstein A; Schiffman J; Tang R; Nelson C; Salvi M; Wester S; Sherman JW; Vescio T; Holt RJ; Smith TJ
    N Engl J Med; 2020 Jan; 382(4):341-352. PubMed ID: 31971679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Teprotumumab: A Review in Thyroid Eye Disease.
    Nie T; Lamb YN
    Drugs; 2022 Nov; 82(17):1663-1670. PubMed ID: 36418673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Teprotumumab: a disease modifying treatment for graves' orbitopathy.
    Ting M; Ezra DG
    Thyroid Res; 2020; 13():12. PubMed ID: 32636936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Teprotumumab: Interpreting the Clinical Trials in the Context of Thyroid Eye Disease Pathogenesis and Current Therapies.
    Winn BJ; Kersten RC
    Ophthalmology; 2021 Nov; 128(11):1627-1651. PubMed ID: 33930408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Teprotumumab in thyroid eye disease.
    Goldberg H; Malik AI
    Saudi J Ophthalmol; 2024; 38(1):29-33. PubMed ID: 38628412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Novel Case of Hyperglycemic Hyperosmolar State After the Use of Teprotumumab in a Patient With Thyroid Eye Disease.
    Shah K; Charitou M
    AACE Clin Case Rep; 2022; 8(4):148-149. PubMed ID: 35959086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X Study.
    Douglas RS; Kahaly GJ; Ugradar S; Elflein H; Ponto KA; Fowler BT; Dailey R; Harris GJ; Schiffman J; Tang R; Wester S; Jain AP; Marcocci C; Marinò M; Antonelli A; Eckstein A; Führer-Sakel D; Salvi M; Sile S; Francis-Sedlak M; Holt RJ; Smith TJ
    Ophthalmology; 2022 Apr; 129(4):438-449. PubMed ID: 34688699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Refractory Thyroid Eye Disease Unresponsive to Teprotumumab: A Case Report.
    Singh G; Taylor B; Michalek S
    Cureus; 2023 Nov; 15(11):e48861. PubMed ID: 38111423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Efficacy of Teprotumumab in Thyroid Eye Disease: Follow-Up Outcomes in Three Clinical Trials.
    Kahaly GJ; Subramanian PS; Conrad E; Holt RJ; Smith TJ
    Thyroid; 2024 Jun; ():. PubMed ID: 38824618
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity.
    Douglas RS; Couch S; Wester ST; Fowler BT; Liu CY; Subramanian PS; Tang R; Nguyen QT; Maamari RN; Ugradar S; Hsu K; Karon M; Stan MN
    J Clin Endocrinol Metab; 2023 Dec; 109(1):25-35. PubMed ID: 37925673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New-Onset of Inflammatory Bowel Disease in a Patient Treated With Teprotumumab for Thyroid Associated Ophthalmopathy.
    Ashraf DC; Jankovic I; El-Nachef N; Winn BJ; Kim GE; Kersten RC
    Ophthalmic Plast Reconstr Surg; 2021 Sep-Oct 01; 37(5):e160-e164. PubMed ID: 33710035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medical Therapy in Patients with Moderate to Severe, Steroid-Resistant, Thyroid Eye Disease.
    Toro-Tobon D; Rachmasari KN; Bradley EA; Wagner LH; Tooley AA; Stokken JK; Stan MN
    Thyroid; 2023 Oct; 33(10):1237-1244. PubMed ID: 37515425
    [No Abstract]   [Full Text] [Related]  

  • 16. Teprotumumab for non-inflammatory thyroid eye disease (TED): evidence for increased IGF-1R expression.
    Ugradar S; Shi L; Wang Y; Mester T; Yang H; Douglas RS
    Eye (Lond); 2021 Sep; 35(9):2607-2612. PubMed ID: 33221815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid response of thyroid eye disease, peripheral edema, and acropathy to teprotumumab infusion.
    Kelly DA; Turbin RE
    Am J Ophthalmol Case Rep; 2024 Jun; 34():102031. PubMed ID: 38487336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Teprotumumab (Tepezza): from the discovery and development of medicines to USFDA approval for active thyroid eye disease (TED) treatment.
    Ali F; Chorsiya A; Anjum V; Ali A
    Int Ophthalmol; 2021 Apr; 41(4):1549-1561. PubMed ID: 33481154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early experience with teprotumumab for chronic thyroid eye disease.
    Ozzello DJ; Kikkawa DO; Korn BS
    Am J Ophthalmol Case Rep; 2020 Sep; 19():100744. PubMed ID: 32462101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of Teprotumumab-Induced Hearing Loss With Comparable Efficacy Using Half-Dose Therapy.
    Phansalkar R; Lu T; Alyono J; Lee J; Dosiou C; Kossler AL
    Ophthalmic Plast Reconstr Surg; 2023 Jul-Aug 01; 39(4):e101-e104. PubMed ID: 36877549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.